What you need to know The prevalence of heart failure across Europe is estimated to be 1-2% of adults.1 In the UK, this places a substantial burden on patients and healthcare resources, including ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results